Emmanuel Normant

Emmanuel Normant

Company: TG Therapeutics

Job title: VP Preclinical Sciences

Seminars:

TG-1801 is a Novel Bispecific CD19-CD47 Antibody Now In Clinic, Tested as a Single Agent or in Combination With Ublituximab 12:00 pm

TG-1801 is a Bispecific CD19-CD47 antibody in clinic Preclinical combination data with anti-CD20 antibody (TG-1801) or small molecules are presentedRead more

day: Clinical Development – Day 2 am

Panel Discussion: Evaluating the Synergistic Potential of Combination with Other Frontline Treatments to Distinguish the Best Combination Approach 4:00 pm

Combining macrophage therapy with Radiotherapy Utilizing other small molecules (e.g. PARP inhibitors, STING agonists) with first-in-class antibody targeting the myeloid-specific ILT4 receptor Developing clinical trial strategy to determine which combinations have the most synergistic/additive potentialRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.